• Цитологическое заключение в соответствии с терминологической системой The Bethesda system 2014 года: что нового?

Цитологическое заключение в соответствии с терминологической системой The Bethesda system 2014 года: что нового?

HEALTH OF WOMAN. 2017.3(119):82–84; doi 10.15574/HW.2017.119.82

Рыкова О. В., Богомаз Т. П.
Медицинская лаборатория «Синэво»
Продолжение. Начало в «Здоровье женщины» № 1, 2, 2017 г.

В статье представлены принципы формирования заключений по результатам ПАП-теста в соответствии с терминологической системой Бетесда 2014 года и корреляция их с заключениями по другим классификациям цитологических выводов.

Ключевые слова: рак шейки матки, цервикальный скрининг, традиционная цитология, жидкостная цитология, ПАП-тест, The Bethesda system.

Литература:
1. Wright TC, Stoler MH, Sharma A et al: Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol 2011;136:578-586. https://doi.org/10.1309/AJCPTUS5EXAS6DKZ; PMid:21917680

2. FDA Approves First Human Papillomavirus Test for Primary Cervical Cancer Screening [News]. Silver Spring, Md: Food and Drug Administration, 2014. Available online. Last accessed September 18, 2014.

3. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119: 1095-101. https://doi.org/10.1002/ijc.21955; PMid:16586444

4. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-35. https://doi.org/10.1002/ijc.25396; PMid:20473886

5. Bulk S, Visser O, Rozendaal L, Verheijen RH, Meijer CJ. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. Br J Cancer 2003; 89: 834-9. https://doi.org/10.1038/sj.bjc.6601157; PMid:12942114 PMCid:PMC2394479

6. Confortini M, Bergeron C, Desai M, Negri G, Dalla PP, Montanari G et al. Accuracy of liquid-based cytology: comparison of the results obtained within a randomized controlled trial (the New Technologies for Cervical Cancer Screening Study) and an external group of experts. Cancer Cytopathol 2010; 118: 203-8. https://doi.org/10.1002/cncy.20081; PMid:20731006

7. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F

8. Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Luthge A, Bergeron C et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-staine cytology. Gynecol Oncol 2011.

9. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D et al. Against which human papillomavirus types shall we vaccinate and screen? the international perspective. Int J Cancer 2004; 111: 278-85. https://doi.org/10.1002/ijc.20244; PMid:15197783

10. Overmeer RM, Henken FE, Bierkens M, Wilting SM, Timmerman I, Meijer CJ et al. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol 2009; 219: 327-36. https://doi.org/10.1002/path.2598; PMid:19662663

11. European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, Daniel J, von Karsa L, European Commission, editors. Luxembourg: Office for Official Publications of the European Communities, 2008. pp. 1-291.

12. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006; 24 (SUPPL. 3): S78-S89. https://doi.org/10.1016/j.vaccine.2006.05.117; PMid:16950021

13. Herbert A., C. Bergeron, H. Wiener, U. Schenck, P. Klinkhamer, J. Bulten, M. Arby. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology 2007, 18, 213–219. https://doi.org/10.1111/j.1365-2303.2007.00469.x; PMid:17635161

14. Arbyn M., A. Anttila, J. Jordan, G. Ronco, U. Schenck, N. Segnan, H.G. Wiener, A. Herbert, J. Daniel (technical editor), L. von Karsa. European guidelines for quality assurance in cervical cancer screening Second Edition, 2008.

15. The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes. Springer. 3rd Edition. Nayar, Ritu; Wilbur, David C. (Eds), 2015.

16. Solomon D: Foreword; in Nayar R, Wilbur DC (eds): The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes, ed 3. New York, Springer 2015. https://doi.org/10.1016/j.crhy.2015.05.006

17. Nayar R, Wilbur DC. The Pap Test and Bethesda 2014. «The reports of my demise have been greatly exaggerated». Acta Cytol. 2015;59(2):121-32. https://doi.org/10.1159/000381842. Epub 2015 May 19.